2002 Update to the ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: Implications for emergency department practice

Annals of Emergency Medicine

Volumn 41, Issue 3, 2003, Pages 355-369

  Pollack Jr , Charles V ^a   Roe, Matthew T ^b   Peterson, Eric D ^b  

^a PENNSYLVANIA HOSPITAL   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; GLYCERYL TRINITRATE; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; MORPHINE SULFATE; TIROFIBAN; TROPONIN;

ANAMNESIS; ANGINA PECTORIS; ANGIOCARDIOGRAPHY; CARDIOVASCULAR RISK; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; EMERGENCY TREATMENT; EMERGENCY WARD; EVIDENCE BASED MEDICINE; HEALTH CARE POLICY; HEART CATHETERIZATION; HEART HEMODYNAMICS; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEMODYNAMIC MONITORING; HUMAN; ISCHEMIC HEART DISEASE; MEDICAL PRACTICE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK MANAGEMENT; ST SEGMENT; TREATMENT INDICATION; UNSTABLE ANGINA PECTORIS;

EID: 0037372251     PISSN: 01960644     EISSN: None     Source Type: Journal    
DOI: 10.1067/mem.2003.88     Document Type: Review

References (45)

1. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Unstable Angina). J Am Coll Cardiol. 2000;36:970-1062. Updated March 2002 at http://www.acc.org and http://www.americanheart.org.
2. Braunwald E, Mark DB, Jones RH, et al. Unstable Angina: Diagnosis and Management. Rockville, MD: Agency for Health Care Policy and Research and the National Heart, Lung, and Blood Institute, US Public Health Service, US Department of Health and Human Services; 1994:1. AHCPR publication No 94-0602.
3. Pollack CV Jr, Gibler WB. 2000 ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: a practical summary for emergency physicians. Ann Emerg Med. 2001;38:229-240.
4. Pollack CV Jr, Gibler WB. Advances create opportunities: implementing the major tenets of the new unstable angina guidelines in the emergency department. Ann Emerg Med. 2001;38:241-248.
5. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction - 2002: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). Circulation. 2002;106:1893-1900.
6. National Center for Health Statistics. Detailed Diagnoses and Procedures: National Hospital Discharge Survey, 1996. Hyattsville, MD: National Center for Health Statistics; 1996.
7. Nouraj P. National Hospital Ambulatory Medical Care Survey: 1997 Emergency Department Summary. Hyattsville, MD: National Center for Health Statistics; 1997.
8. American College of Cardiology Web site. Available at: http://www.acc.org/ clinical/guidelines/nov96/1999/index.htm. Accessed January 21, 2003.
9. Storrow AB, Gibler WB. Chest pain centers: diagnosis of acute coronary syndrome. Ann Emerg Med. 2000;35:449-461.
10. Boersma E, Pieper KS, Steyerberg EW, et al. Predictors of outcomes in patients with a cute coronary syndromes without persistent ST-segment elevation: results for an international trial of 9461 patients. Circulation. 2000;101:2557-2567.
11. Antman EM, Cohen M, Bernink PJ, et al. The TIMI risk score for unstable angina/non-ST elevatian MI: a method for prognostication and therapeutic decision making. JAMA. 2000;284:835-842.
12. Antman EM, McCabe CH, Gurfinkel EP, et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 11B trial. Circulation. 1999;100:1593-1601.
13. Cohen M, Demers C, Gurfinkel EP, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med. 1997;337:447-452.
14. Cannon CP, Weintraub WS, Demopoulos LA, et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med. 2001;344:1879-1887.
15. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction [published erratum appears in N Engl J Med. 1998;339:415]. N Engl J Med. 1998;338:1488-1497.
16. Morrow DA, Antman EM, Snapinn S, et al. An integrated clinical approach to predicting the benefit of tirofiban in non-ST elevation acute coronary syndromes: application of the TIMI risk score for UA/NSTEMI in PRISM-PLUS. Eur Heart J. 2002;23:223-229.
17. Clinical Trial Results Web site. Available at: http://www.clinicaltrialresults.org. Accessed January 21, 2003.
18. Myocardial infarction redefined - a consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol. 2000;36:959-969.
19. Ohman EM, Armstrong PW, Christenson RH, et al. Cardiac troponin T levels for risk stratification in acute myocardial ischemia. N Engl J Med. 1996;335:1333-1341.
20. Antman EM, Tanasijevic MJ, Thompson B, et al. Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N Engl J Med. 1996;335:1342-1349.
21. Pettijohn TL, Doyle T, Spiekerman AM, et al. Usefulness of positive troponin-T and negative creatine kinase levels in identifying high-risk patients with unstable angina pectoris. Am J Cardiol. 1997;80:510-511.
22. Lindahl B, Andren B, Ohlsson J, et al. Risk stratification in unstable coronary artery disease: additive value of troponin T determinations and pre-discharge exercise tests. FRISC Study Group. Eur Heart J. 1997;18:762-770.
23. Jesse RL, Crosby PA. The role of a biochemical marker for ischemia in the management of acute coronary syndrome patients. Oral presentation at: World Congress of Cardiology; May 2002; Sydney, New South Wales, Australia.
24. Fragmin and Fast Revascularisation During Instability in Coronary Artery Disease Investigators. Invasive compared with non-invasive treatment in unstable coronaryartery disease: FRISC II prospective randomised multicentre study. Lancet. 1999;354:708-715.
25. PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIa/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med. 1998;339:436-443.
26. Bhatt DL, Marso SP, Houghtaling P, et al. Does earlier administration of eptifibatide reduce death and MI in patients with acute coronary syndromes? Circulation. 1998;98(Suppl 1):1560-1561.
27. Greenbaum AB, Harrington RA, Hudson MP, et al. Therapeutic value of eptifibatide at community hospitals transferring patients to tertiary referral centers early after admission for acute coronary syndromes. J Am Coll Cardiol. 2001;37:492-498.
28. Theroux P, Alexander J Jr, Dupuis J, et al. Upstream use of tirofiban in patients admitted for an acute coronary syndrome in hospitals with or without facilities for invasive management. Am J Cardiol. 2001;87:375-380.
29. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494-502.
30. PARAGON Investigators. Platelet IIb/IIIa antagonism for the reduction of acute coronary syndrome events in a global organizational network. Circulation. 1998;97:2386-2395.
31. Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001;358:527-533.
32. Collet J P, Montalescot G, Lison L, et al. Percutaneous coronary intervention after subcutaneous enoxaparin pretreatment in patients with unstable angina pectoris. Circulation. 2001;103:658-663.
33. Kereiakes DJ, Grines C, Fry E, et al. Enoxaparin and abciximab adjunctive pharmacotherapy during percutaneous coronary intervention. J Invasive Cardiol. 2001;13:272-278.
34. Klein W, Buchwald A, Hillis SE, et al. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. FRagmin In unstable Coronary artery disease study (FRIC) [published erratum appears in Circulation. 1998;97:413]. Circulation. 1997;96:61-68.
35. Michalis LK, Papamichail N, Katsouras C, et al. Enoxaparin versus tinzaparin in the management of unstable coronary artery disease (EVET Study) [abstract]. J Am Coll Cardiol. 2001;37:365a.
36. Xiao Z, Theroux P. Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor. Circulation. 1998;97:251-256.
37. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med. 1995;332:1330-1335.
38. Cohen M, Theroux P, Frey MJ, et al. Anti-thrombotic combination using tirofiban and enoxaparin: the ACUTE II Study [abstract]. Circulation. 2000;102(Suppl II):II826.
39. Young JJ, Kereiakes DJ, Grines CL. Low-molecular-weight heparin therapy in percutaneous coronary intervention: the NICE 1 and NICE 4 trials. National Investigators Collaborating on Enoxaparin Investigators. J Invasive Cardiol. 2000;12(Suppl E):E14-E18.
40. Kereiakes DJ, Kleiman NS, Fry E, et al. Dalteparin in combination with abciximab during percutaneous coronary intervention. Am Heart J. 2001;141:348-352.
41. Goodman SG, Fitchett D, Armstrong PW, et al, for the INTERACT Trial Investigators. Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Circulation. 2003;107:238-244.
42. Schriger DL, Herbert ME. Platelet glycoprotein inhibitors in patients with medically managed acute coronary syndrome: does the enthusiasm exceed the science? Ann Emerg Med. 2001;38:229-240.
43. Simoons ML. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial. Lancet. 2001;357:1915-1924.
44. Boersma E, Harrington RA, Moliterno DJ, et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a metaanalysis of all major randomised clinical trials. Lancet. 2002;359:189-198.
45. Pollack CV Jr, Cohen M. Outcome-effective management of acute coronary syndromes: guidelines, protocols, and recommendations for emergency medical practice. CEVAT Panel Reports. 2002;1:1-20.